AI-generated analysis. Always verify with the original filing.
Kiora Pharmaceuticals reported fourth-quarter and full-year 2025 financial results, including a net loss of $10.8 million for the year compared to net income of $3.6 million in 2024, and ended the year with $17.1 million in cash, cash equivalents, and short-term investments. The company advanced Phase 2 clinical trials for KIO-301 in retinitis pigmentosa and KIO-104 in macular edema, with cash expected to fund operations into late 2027.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Thi
. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Title 99.1 Press Release of Kiora Pharmaceuticals, Inc., dated as of March 25, 2026 104 Cover
| Metric | Value | Basis |
|---|---|---|
| Revenue | $0.00 | GAAP |
| Net Loss | $10.80 | GAAP |
| Net Loss | $6.50 | GAAP |
| Net Loss per Common Share - Basic | $2.60 | GAAP |